Filtros de búsqueda

Lista de obras de

"Laying on of hands" improves well-being in patients with advanced cancer.

artículo científico publicado en 2006

A practical update on the use of bortezomib in the management of multiple myeloma

artículo científico publicado en 2006

A predictive model for risk of early grade ≥ 3 infection in patients with multiple myeloma not eligible for transplant: analysis of the FIRST trial.

artículo científico publicado en 2018

A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial

scientific article published on 19 August 2019

Additional lesions detected in therapeutic scans with 177Lu-DOTATATE reflect higher affinity of 177Lu-DOTATATE for somatostatin receptors

artículo científico publicado en 2011

An European Myeloma Network recommendation on tools for diagnosis and monitoring of multiple myeloma: what to use and when

scholarly article by Jo Caers et al published 31 August 2018 in Haematologica

Association between response kinetics and outcomes in relapsed/refractory multiple myeloma: analysis from TOURMALINE-MM1

artículo científico publicado en 2018

Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95):

scientific article published on 30 April 2020

Background and methodology of MONITOR-GCSF, a pharmaco-epidemiological study of the multi-level determinants, predictors, and clinical outcomes of febrile neutropenia prophylaxis with biosimilar granulocyte-colony stimulating factor filgrastim

artículo científico publicado en 2010

Bendamustine-bortezomib-dexamethasone is an active and well-tolerated regimen in patients with relapsed or refractory multiple myeloma

artículo científico publicado en 2013

Benefits and risks of using erythropoiesis-stimulating agents (ESAs) in lung cancer patients: study-level and patient-level meta-analyses

artículo científico publicado en 2012

Bortezomib, thalidomide and dexamethasone, with or without cyclophosphamide, for patients with previously untreated multiple myeloma: 5-year follow-up.

artículo científico publicado en 2015

Cancer-related anemia: biological findings, clinical implications and impact on quality of life

artículo científico publicado en 2005

Cardiovascular adverse events in modern myeloma therapy - incidence and risks. A review from European Myeloma Network (EMN) and Italian Society of Arterial Hypertension (SIIA)

article

Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study

artículo científico publicado en 2015

Carfilzomib and dexamethasone versus eight cycles of bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma: an indirect comparison using data from the phase 3 ENDEAVOR and CASTOR trials

artículo científico publicado en 2019

Carfilzomib and dexamethasone vs bortezomib and dexamethasone in patients with relapsed multiple myeloma: results of the phase 3 study ENDEAVOR (NCT01568866) according to age subgroup.

artículo científico publicado en 2017

Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial

artículo científico publicado en 2017

Carfilzomib vs bortezomib in patients with multiple myeloma and renal failure: a subgroup analysis of ENDEAVOR

scholarly article by Athanasios Dimopoulos et al published 10 January 2019 in Blood

Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma

article

Carfilzomib, lenalidomide, and dexamethasone in patients with relapsed multiple myeloma categorised by age: secondary analysis from the phase 3 ASPIRE study

artículo científico publicado en 2017

Carfilzomib-Dexamethasone Versus Bortezomib-Dexamethasone in Relapsed or Refractory Multiple Myeloma: Updated Overall Survival, Safety, and Subgroups

artículo científico publicado en 2019

Carfilzomib-dexamethasone versus subcutaneous or intravenous bortezomib in relapsed or refractory multiple myeloma: secondary analysis of the phase 3 ENDEAVOR study

artículo científico publicado en 2017

Cereblon expression in multiple myeloma: not ready for prime time - response to Lodé et al

artículo científico publicado en 2013

Chimeric antigen receptor T-cell therapy for multiple myeloma: a consensus statement from The European Myeloma Network

scientific article published on 22 August 2019

Chromosomal aberrations are shared by malignant plasma cells and a small fraction of circulating CD19+ cells in patients with myeloma and monoclonal gammopathy of undetermined significance

artículo científico publicado en 2002

Combined phase I/II study of imexon (AOP99.0001) for treatment of relapsed or refractory multiple myeloma

artículo científico publicado en 2010

Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma (short title)

artículo científico publicado en 2015

Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3.

artículo científico publicado en 2011

Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1.

artículo científico publicado en 2011

Continuous prednisolone versus conventional prednisolone with VMCP-interferon-alpha2b as first-line chemotherapy in elderly patients with multiple myeloma.

artículo científico publicado en 2005

Current multiple myeloma treatment strategies with novel agents: a European perspective

scientific article published on 19 January 2010

Darbepoetin alfa for treating chemotherapy-induced anemia in patients with a baseline hemoglobin level < 10 g/dL versus > or = 10 g/dL: an exploratory analysis from a randomized, double-blind, active-controlled trial

artículo científico publicado en 2009

Darbepoetin alpha for the treatment of anemia in patients with active cancer not receiving chemotherapy or radiotherapy: results of a phase III, multicenter, randomized, double-blind, placebo-controlled study

scientific article published on 28 January 2008

Design and rationale of FOCUS (PX-171-011): a randomized, open-label, phase 3 study of carfilzomib versus best supportive care regimen in patients with relapsed and refractory multiple myeloma (R/R MM)

artículo científico publicado en 2012

ESAs not the culprit: more studies required

artículo científico publicado en 2008

Einsatz von Erythropoese-stimulierenden Proteinen bei anämischen Patienten mit malignen Erkrankungen

scientific article published on 01 January 2008

Erratum to: Iron metabolism and iron supplementation in cancer patients

artículo científico publicado en 2015

Erratum to: Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma.

artículo científico publicado en 2016

Erratum to: Treatment patterns and outcomes in the prophylaxis of chemotherapy-induced (febrile) neutropenia with biosimilar filgrastim (the MONITOR-GCSF study)

artículo científico publicado en 2016

European Myeloma Network guidelines for the management of multiple myeloma-related complications

artículo científico publicado en 2015

European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma

artículo científico publicado en 2014

European Myeloma Network: the 3rd Trialist Forum Consensus Statement from the European experts meeting on multiple myeloma.

artículo científico publicado en 2010

European perspective on multiple myeloma treatment strategies in 2014

artículo científico publicado en 2014

European perspective on multiple myeloma treatment strategies: update following recent congresses

artículo científico publicado en 2012

Experience with lenalidomide in an Austrian non-study population with advanced myelofibrosis.

artículo científico publicado en 2013

Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma

artículo científico publicado en 2017

Flow Cytometric Evaluation of Traditional and Novel Surface Markers for the Diagnosis of Plasma Cell Dyscrasias

scientific article published on 07 March 2019

From transplant to novel cellular therapies in multiple myeloma: European Myeloma Network guidelines and future perspectives

artículo científico publicado en 2018

Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report

artículo científico publicado en 2015

Health-Related Quality of Life Results From the Open-Label, Randomized, Phase III ASPIRE Trial Evaluating Carfilzomib, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone in Patients With Relapsed Multiple Myeloma.

artículo científico publicado en 2016

Health-related quality of life in the ENDEAVOR study: carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed/refractory multiple myeloma

article

Health-related quality of life of carfilzomib- and daratumumab-based therapies in patients with relapsed/refractory multiple myeloma, based on German benefit assessment data

artículo científico publicado en 2019

High expression of cereblon (CRBN) is associated with improved clinical response in patients with multiple myeloma treated with lenalidomide and dexamethasone.

artículo científico publicado en 2013

How I manage the toxicities of myeloma drugs.

artículo científico publicado en 2017

IKAROS expression in distinct bone marrow cell populations as a candidate biomarker for outcome with lenalidomide-dexamethasone therapy in multiple myeloma

artículo científico publicado en 2017

IMWG consensus on maintenance therapy in multiple myeloma

artículo científico publicado en 2012

Improvement in Overall Survival With Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

artículo científico publicado en 2018

Induction of indoleamine-2,3 dioxygenase in bone marrow stromal cells inhibits myeloma cell growth

artículo científico publicado en 2012

Insights on Multiple Myeloma Treatment Strategies

artículo científico publicado en 2018

International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment

artículo científico publicado en 2016

International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation

artículo científico publicado en 2011

International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma

artículo científico publicado en 2016

International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders

scientific article published on 01 June 2019

International staging system for multiple myeloma

artículo científico publicado en 2005

Intravenous iron alone resolves anemia in patients with functional iron deficiency and lymphoid malignancies undergoing chemotherapy

artículo científico publicado en 2014

Iron metabolism and iron supplementation in cancer patients

artículo científico publicado en 2015

Ixazomib-Thalidomide-Dexamethasone for induction therapy followed by Ixazomib maintenance treatment in patients with relapsed/refractory multiple myeloma

scientific article published on 27 September 2019

Lenalidomide and dexamethasone for acute light chain-induced renal failure: a phase II study

artículo científico publicado en 2014

Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma

artículo científico publicado en 2014

Lenalidomide downregulates the cell survival factor, interferon regulatory factor-4, providing a potential mechanistic link for predicting response

artículo científico publicado en 2011

Lenalidomide in combination with dexamethasone for the treatment of relapsed or refractory multiple myeloma

artículo científico publicado en 2008

Light chain-induced acute renal failure can be reversed by bortezomib-doxorubicin-dexamethasone in multiple myeloma: results of a phase II study.

artículo científico publicado en 2010

Maintenance Treatment and Survival in Patients With Myeloma: A Systematic Review and Network Meta-analysis

artículo científico publicado en 2018

Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma

artículo científico publicado en 2017

Management of complications in multiple myeloma

artículo científico publicado en 2009

Management of disease-related anemia in patients with multiple myeloma or chronic lymphocytic leukemia: epoetin treatment recommendations

artículo científico publicado en 2002

Management of multiple myeloma with bortezomib: experts review the data and debate the issues

artículo científico publicado en 2006

Management of patients with multiple myeloma in the era of COVID-19 pandemic: a consensus paper from the European Myeloma Network (EMN)

scientific article published on 22 May 2020

Maternal embryonic leucine zipper kinase inhibitor OTSSP167 has preclinical activity on multiple myeloma bone disease.

artículo científico publicado en 2018

Maternal embryonic leucine zipper kinase is a novel target for proliferation-associated high-risk myeloma

artículo científico publicado en 2017

Minimal Residual Disease Status as a Surrogate Endpoint for Progression-free Survival in Newly Diagnosed Multiple Myeloma Studies: A Meta-analysis

artículo científico publicado en 2019

Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens

artículo científico publicado en 2009

Molecular mechanisms, current management and next generation therapy in myeloma bone disease.

artículo científico publicado en 2017

Monokine induced by interferon gamma (MIG/CXCL9) is an independent prognostic factor in newly diagnosed myeloma

artículo científico publicado en 2016

Multiple Myeloma Incidence and Mortality around the Globe; Interrelations between Health Access and Quality, Economic Resources, and Patient Empowerment

scientific article published on 25 April 2020

Multiple myeloma treatment strategies with novel agents in 2011: a European perspective

scientific article published on 26 March 2011

MyelomA Genetics International Consortium

artículo científico

Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival: an analysis of 10 549 patients from the International Myeloma Working Group

artículo científico publicado en 2008

Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation

artículo científico publicado en 2003

Novel therapeutic agents for the management of patients with multiple myeloma and renal impairment.

artículo científico publicado en 2012

Overexpression of G protein-coupled receptor 5D in the bone marrow is associated with poor prognosis in patients with multiple myeloma

artículo científico publicado en 2012

Patient With High-Grade Fever, Night Sweats, and Hepatosplenomegaly ⬇️

artículo científico publicado el 10 de enero de 2011

Patient-centered practice in elderly myeloma patients: an overview and consensus from the European Myeloma Network (EMN)

Patterns of somatic mutations in VH genes reveal pathways of clonal transformation from MGUS to multiple myeloma.

artículo científico publicado en 2003

Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN).

artículo científico publicado en 2011

Pharmacovigilance in practice: erythropoiesis-stimulating agents

artículo científico publicado en 2014

Pooled analysis of individual patient-level data from all randomized, double-blind, placebo-controlled trials of darbepoetin alfa in the treatment of patients with chemotherapy-induced anemia

artículo científico publicado en 2009

Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma

artículo científico publicado en 2016

Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network.

artículo científico publicado en 2018

Primary immune thrombocytopenia in adults: diagnostics and treatment consensus statement of the Austrian Society of Hematology and Oncology (ÖGHO)

artículo científico publicado en 2012

Proteasome inhibition and its clinical prospects in the treatment of hematologic and solid malignancies

artículo científico publicado en 2005

Publisher Correction: The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group

scientific article published on 01 February 2019

Quality of life in patients with relapsed/refractory multiple myeloma during ixazomib-thalidomide-dexamethasone induction and ixazomib maintenance therapy and comparison to the general population

artículo científico publicado en 2019

Randomized phase II study of bortezomib, thalidomide, and dexamethasone with or without cyclophosphamide as induction therapy in previously untreated multiple myeloma

artículo científico publicado en 2012

Randomized phase III study (ADMYRE) of plitidepsin in combination with dexamethasone vs. dexamethasone alone in patients with relapsed/refractory multiple myeloma

artículo científico publicado en 2019

Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network

artículo científico publicado en 2020

Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group

artículo científico publicado en 2010

Response to the publication: EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer

scientific article published on 25 October 2005

Reversal of acute renal failure by bortezomib-based chemotherapy in patients with multiple myeloma

artículo científico publicado en 2007

Rituximab treatment provides no clinical benefit in patients with pretreated advanced multiple myeloma

scientific article published on 01 June 2006

Role of magnetic resonance imaging in the management of patients with multiple myeloma: a consensus statement

artículo científico publicado en 2015

Successful treatment of a patient with lymphocyte-predominant Hodgkin's lymphoma with yttrium-90-ibritumomab tiuxetan

scientific article published on 08 July 2008

Superiority of the triple combination of bortezomib-thalidomide-dexamethasone over the dual combination of thalidomide-dexamethasone in patients with multiple myeloma progressing or relapsing after autologous transplantation: the MMVAR/IFM 2005-04 R

artículo científico publicado en 2012

Suppression of the noninvolved pair of the myeloma isotype correlates with poor survival in newly diagnosed and relapsed/refractory patients with myeloma

artículo científico publicado en 2015

Survival and years of life lost in different age cohorts of patients with multiple myeloma.

artículo científico publicado en 2010

Targeting of BMI-1 with PTC-209 shows potent anti-myeloma activity and impairs the tumour microenvironment

artículo científico publicado en 2016

Thalidomide for treatment of multiple myeloma: 10 years later

artículo científico publicado en 2008

Thalidomide maintenance treatment increases progression-free but not overall survival in elderly patients with myeloma.

artículo científico publicado en 2010

Thalidomide-dexamethasone compared with melphalan-prednisolone in elderly patients with multiple myeloma

artículo científico publicado en 2008

The Changing Landscape of Smoldering Multiple Myeloma: A European Perspective

artículo científico publicado en 2016

The anti-mitotic agents PTC-028 and PTC596 display potent activity in pre-clinical models of multiple myeloma but challenge the role of BMI-1 as an essential tumour gene

scientific article published on 30 March 2020

The clinical relevance and management of monoclonal gammopathy of undetermined significance and related disorders: recommendations from the European Myeloma Network

artículo científico publicado en 2014

The current landscape of multiple myeloma treatment

artículo científico publicado en 2008

The development and validation of a prediction tool for chemotherapy-induced anemia in patients with advanced nonsmall cell lung cancer receiving palliative chemotherapy

artículo científico publicado en 2006

The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group

artículo científico publicado en 2019

The role of histone deacetylase inhibitors in patients with relapsed/refractory multiple myeloma

artículo científico

The serum heavy/light chain immunoassay: A valuable tool for sensitive paraprotein assessment, risk, and disease monitoring in monoclonal gammopathies.

artículo científico publicado en 2017

Threatening clots in MGUS and myeloma

artículo científico publicado en 2010

Transfusion risk in cancer patients with chemotherapy-induced anemia when initiating darbepoetin alfa therapy at a baseline hemoglobin level of <9 g/dL versus 9 to <10 g/dL versus ≥ 10 g/dL: an exploratory analysis of a phase 3 trial

scientific article published on 13 November 2011

Treatment of relapsed and refractory multiple myeloma in the era of novel agents

artículo científico publicado en 2010

Treatment patterns and outcomes in the management of anaemia in cancer patients in Europe: findings from the Anaemia Cancer Treatment (ACT) study.

artículo científico publicado en 2009

Treatment patterns and outcomes in the prophylaxis of chemotherapy-induced (febrile) neutropenia with biosimilar filgrastim (the MONITOR-GCSF study).

artículo científico publicado en 2015

Treatment-related peripheral neuropathy in multiple myeloma: the challenge continues

artículo científico publicado en 2010

Update on the MONITOR-GCSF study of biosimilar filgrastim to reduce the incidence of chemotherapy-induced febrile neutropenia in cancer patients: Protocol amendments ⬇️

artículo científico publicado el 1 de marzo de 2011

[Anemias]

artículo científico publicado en 2006

Dominio Público Uruguay está sostenido por:

Acerca de Dominio Público Uruguay

Ayuda